281 related articles for article (PubMed ID: 34954641)
1. Plumbagin reduction by thioredoxin reductase 1 possesses synergy effects with GLUT1 inhibitor on KEAP1-mutant NSCLC cells.
Sun S; Zhang Y; Xu W; Yang R; Yang Y; Guo J; Ma Q; Ma K; Zhang J; Xu J
Biomed Pharmacother; 2022 Feb; 146():112546. PubMed ID: 34954641
[TBL] [Abstract][Full Text] [Related]
2. Thioredoxin reductase 1 inhibitor shikonin promotes cell necroptosis via SecTRAPs generation and oxygen-coupled redox cycling.
Zhang Y; Sun S; Xu W; Yang R; Yang Y; Guo J; Ma K; Xu J
Free Radic Biol Med; 2022 Feb; 180():52-62. PubMed ID: 34973363
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
4. Thioredoxin reductase-1 levels are associated with NRF2 pathway activation and tumor recurrence in non-small cell lung cancer.
Delgobo M; Gonçalves RM; Delazeri MA; Falchetti M; Zandoná A; Nascimento das Neves R; Almeida K; Fagundes AC; Gelain DP; Fracasso JI; Macêdo GB; Priori L; Bassani N; Bishop AJR; Forcelini CM; Moreira JCF; Zanotto-Filho A
Free Radic Biol Med; 2021 Dec; 177():58-71. PubMed ID: 34673143
[TBL] [Abstract][Full Text] [Related]
5. TrxR1 as a potent regulator of the Nrf2-Keap1 response system.
Cebula M; Schmidt EE; Arnér ES
Antioxid Redox Signal; 2015 Oct; 23(10):823-53. PubMed ID: 26058897
[TBL] [Abstract][Full Text] [Related]
6. KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer.
Dai B; Yoo SY; Bartholomeusz G; Graham RA; Majidi M; Yan S; Meng J; Ji L; Coombes K; Minna JD; Fang B; Roth JA
Cancer Res; 2013 Sep; 73(17):5532-43. PubMed ID: 23824739
[TBL] [Abstract][Full Text] [Related]
7. Details in the catalytic mechanism of mammalian thioredoxin reductase 1 revealed using point mutations and juglone-coupled enzyme activities.
Xu J; Cheng Q; Arnér ES
Free Radic Biol Med; 2016 May; 94():110-20. PubMed ID: 26898501
[TBL] [Abstract][Full Text] [Related]
8. Inducing ubiquitination and degradation of TrxR1 protein by LW-216 promotes apoptosis in non-small cell lung cancer via triggering ROS production.
Wang R; Zhong L; Wang T; Sun T; Yang J; Liu X; Wu Y; Guo Q; Gao Y; Zhao K
Neoplasia; 2024 Jul; 53():101004. PubMed ID: 38733769
[TBL] [Abstract][Full Text] [Related]
9. [Selenoprotein thioredoxin reductase mediated menadione reduction: catalytic properties & inhibition effects].
Zhang N; Sun S; Zhang Y; Yang Y; Zhang Y; Chen J; Xu W; Ma Q; Xu J
Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):2139-2150. PubMed ID: 33169578
[TBL] [Abstract][Full Text] [Related]
10. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.
Peng X; Zhang MQ; Conserva F; Hosny G; Selivanova G; Bykov VJ; Arnér ES; Wiman KG
Cell Death Dis; 2013 Oct; 4(10):e881. PubMed ID: 24157875
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
[TBL] [Abstract][Full Text] [Related]
12. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine.
Anestål K; Arnér ES
J Biol Chem; 2003 May; 278(18):15966-72. PubMed ID: 12574159
[TBL] [Abstract][Full Text] [Related]
13. Interplay between cytosolic disulfide reductase systems and the Nrf2/Keap1 pathway.
Schmidt EE
Biochem Soc Trans; 2015 Aug; 43(4):632-8. PubMed ID: 26551704
[TBL] [Abstract][Full Text] [Related]
14. The role of thioredoxin reductase and glutathione reductase in plumbagin-induced, reactive oxygen species-mediated apoptosis in cancer cell lines.
Hwang GH; Ryu JM; Jeon YJ; Choi J; Han HJ; Lee YM; Lee S; Bae JS; Jung JW; Chang W; Kim LK; Jee JG; Lee MY
Eur J Pharmacol; 2015 Oct; 765():384-93. PubMed ID: 26341012
[TBL] [Abstract][Full Text] [Related]
15. ERBB3 and IGF1R Signaling Are Required for Nrf2-Dependent Growth in KEAP1-Mutant Lung Cancer.
Vartanian S; Lee J; Klijn C; Gnad F; Bagniewska M; Schaefer G; Zhang D; Tan J; Watson SA; Liu L; Chen H; Liang Y; Watanabe C; Cuellar T; Kan D; Hartmaier RJ; Lau T; Costa MR; Martin SE; Merchant M; Haley B; Stokoe D
Cancer Res; 2019 Oct; 79(19):4828-4839. PubMed ID: 31416841
[TBL] [Abstract][Full Text] [Related]
16. Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent.
Wang L; Yang Z; Fu J; Yin H; Xiong K; Tan Q; Jin H; Li J; Wang T; Tang W; Yin J; Cai G; Liu M; Kehr S; Becker K; Zeng H
Free Radic Biol Med; 2012 Mar; 52(5):898-908. PubMed ID: 22210352
[TBL] [Abstract][Full Text] [Related]
17. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
[TBL] [Abstract][Full Text] [Related]
18. Genistein mediates the selective radiosensitizing effect in NSCLC A549 cells via inhibiting methylation of the keap1 gene promoter region.
Liu X; Sun C; Liu B; Jin X; Li P; Zheng X; Zhao T; Li F; Li Q
Oncotarget; 2016 May; 7(19):27267-79. PubMed ID: 27029077
[TBL] [Abstract][Full Text] [Related]
19.
Sitthideatphaiboon P; Galan-Cobo A; Negrao MV; Qu X; Poteete A; Zhang F; Liu DD; Lewis WE; Kemp HN; Lewis J; Rinsurongkawong W; Giri U; Lee JJ; Zhang J; Roth JA; Swisher S; Heymach JV
Clin Cancer Res; 2021 Mar; 27(6):1720-1733. PubMed ID: 33323404
[TBL] [Abstract][Full Text] [Related]
20. Thioredoxin Reductase Inhibition for Cancer Therapy.
Gencheva R; Arnér ESJ
Annu Rev Pharmacol Toxicol; 2022 Jan; 62():177-196. PubMed ID: 34449246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
